Literature DB >> 23617943

Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic inflammation.

Veerle Bieghs1, Sofie M A Walenbergh, Tim Hendrikx, Patrick J van Gorp, Fons Verheyen, Steven W Olde Damink, Ad A Masclee, Ger H Koek, Marten H Hofker, Christoph J Binder, Ronit Shiri-Sverdlov.   

Abstract

BACKGROUND & AIMS: Non-alcoholic steatohepatitis (NASH) is characterized by steatosis and inflammation. The transition from steatosis towards NASH represents a key step in pathogenesis, as it will set the stage for further severe liver damage. Under normal conditions, lipoproteins that are endocytosed by Kupffer cells (KCs) are easily transferred from the lysosomes into the cytoplasm. Oxidized LDL (oxLDL) that is taken up by the macrophages in vitro is trapped within the lysosomes, while acetylated LDL (acLDL) is leading to normal lysosomal hydrolysis, resulting in cytoplasmic storage. We have recently demonstrated that hepatic inflammation is correlated with lysosomal trapping of lipids. So far, a link between lysosomal trapping of oxLDL and inflammation was not established. We hypothesized that lysosomal trapping of oxLDL in KCs will lead to hepatic inflammation.
METHODS: Ldlr(-/-) mice were injected with LDL, acLDL and oxLDL and sacrificed after 2, 6 and 24 h.
RESULTS: Electron microscopy of KCs demonstrated that after oxLDL injection, small lipid inclusions were present inside the lysosomes after all time points and were mostly pronounced after 6 and 24 h. In contrast, no lipid inclusions were present inside KCs after LDL or acLDL injection. Hepatic expression of several inflammatory genes and scavenger receptors was higher after oxLDL injections compared with LDL or acLDL.
CONCLUSIONS: These data suggest that trapping of oxLDL inside lysosomes of KCs in vivo is causally linked to increased hepatic inflammatory gene expression. Our novel observations provide new bases for prevention and treatment of NASH.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Kupffer cells; inflammation; liver; lysosomes; oxLDL

Mesh:

Substances:

Year:  2013        PMID: 23617943      PMCID: PMC4040540          DOI: 10.1111/liv.12170

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  31 in total

Review 1.  The liver as an immunological organ.

Authors:  Vito Racanelli; Barbara Rehermann
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

Review 2.  Low density lipoprotein oxidation and its pathobiological significance.

Authors:  D Steinberg
Journal:  J Biol Chem       Date:  1997-08-22       Impact factor: 5.157

3.  The toxicity to macrophages of oxidized low-density lipoprotein is mediated through lysosomal damage.

Authors:  X M Yuan; W Li; A G Olsson; U T Brunk
Journal:  Atherosclerosis       Date:  1997-09       Impact factor: 5.162

Review 4.  The role of lysosomes in inflammation and disease.

Authors:  G Weissmann
Journal:  Annu Rev Med       Date:  1967       Impact factor: 13.739

5.  In vivo and in vitro uptake and degradation of acetylated low density lipoprotein by rat liver endothelial, Kupffer, and parenchymal cells.

Authors:  J F Nagelkerke; K P Barto; T J van Berkel
Journal:  J Biol Chem       Date:  1983-10-25       Impact factor: 5.157

Review 6.  Advanced atherosclerotic foam cell formation has features of an acquired lysosomal storage disorder.

Authors:  W Gray Jerome
Journal:  Rejuvenation Res       Date:  2006       Impact factor: 4.663

7.  Aggregated LDL and lipid dispersions induce lysosomal cholesteryl ester accumulation in macrophage foam cells.

Authors:  Evelyn E Griffin; Jody C Ullery; Brian E Cox; W Gray Jerome
Journal:  J Lipid Res       Date:  2005-07-16       Impact factor: 5.922

8.  Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36.

Authors:  J Han; D P Hajjar; M Febbraio; A C Nicholson
Journal:  J Biol Chem       Date:  1997-08-22       Impact factor: 5.157

9.  Different fate in vivo of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats. Recognition by various scavenger receptors on Kupffer and endothelial liver cells.

Authors:  T J Van Berkel; Y B De Rijke; J K Kruijt
Journal:  J Biol Chem       Date:  1991-02-05       Impact factor: 5.157

10.  Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.

Authors:  S Ylä-Herttuala; W Palinski; M E Rosenfeld; S Parthasarathy; T E Carew; S Butler; J L Witztum; D Steinberg
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

View more
  33 in total

1.  M1 polarization bias and subsequent nonalcoholic steatohepatitis progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1-induced oxidative stress in obese mice.

Authors:  Ratanesh Kumar Seth; Suvarthi Das; Sahar Pourhoseini; Diptadip Dattaroy; Stephen Igwe; Julie Basu Ray; Daping Fan; Gregory A Michelotti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  J Pharmacol Exp Ther       Date:  2014-10-27       Impact factor: 4.030

Review 2.  The significance of YKL-40 protein in liver fibrosis.

Authors:  Hui Tao; Jing-Jing Yang; Kai-Hu Shi; Cheng Huang; Lei Zhang; Xiong-Wen Lv; Jun Li
Journal:  Inflamm Res       Date:  2014-01-19       Impact factor: 4.575

3.  Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).

Authors:  Gregor Leibundgut; Corey Scipione; Huiyong Yin; Matthias Schneider; Michael B Boffa; Simone Green; Xiaohong Yang; Edward Dennis; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

Review 4.  The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease.

Authors:  Marina Nati; Kyoung-Jin Chung; Triantafyllos Chavakis
Journal:  J Innate Immun       Date:  2021-08-24       Impact factor: 7.349

5.  An optical nanoreporter of endolysosomal lipid accumulation reveals enduring effects of diet on hepatic macrophages in vivo.

Authors:  Thomas V Galassi; Prakrit V Jena; Janki Shah; Geyou Ao; Elizabeth Molitor; Yaron Bram; Angela Frankel; Jiwoon Park; Jose Jessurun; Daniel S Ory; Adriana Haimovitz-Friedman; Daniel Roxbury; Jeetain Mittal; Ming Zheng; Robert E Schwartz; Daniel A Heller
Journal:  Sci Transl Med       Date:  2018-10-03       Impact factor: 17.956

Review 6.  Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.

Authors:  Robert F Schwabe; Ira Tabas; Utpal B Pajvani
Journal:  Gastroenterology       Date:  2020-02-08       Impact factor: 22.682

Review 7.  The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH).

Authors:  Marina Nati; David Haddad; Andreas L Birkenfeld; Christian A Koch; Triantafyllos Chavakis; Antonios Chatzigeorgiou
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

8.  PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a Human Antibody Detects Clinically Relevant Atherothrombosis.

Authors:  Max L Senders; Xuchu Que; Young Seok Cho; Calvin Yeang; Hannah Groenen; Francois Fay; Claudia Calcagno; Anu E Meerwaldt; Simone Green; Phuong Miu; Mark E Lobatto; Thomas Reiner; Zahi A Fayad; Joseph L Witztum; Willem J M Mulder; Carlos Pérez-Medina; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2018-01-23       Impact factor: 24.094

Review 9.  Nonalcoholic Fatty Liver Disease.

Authors:  Lingling Ding; Yvonne Oligschlaeger; Ronit Shiri-Sverdlov; Tom Houben
Journal:  Handb Exp Pharmacol       Date:  2022

Review 10.  The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Detlef Schuppan; Henning Grønbæk; Konstantin Kazankov; Simon Mark Dahl Jørgensen; Karen Louise Thomsen; Holger Jon Møller; Hendrik Vilstrup; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-03       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.